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Chemogenetic technologies, including the muta-
ted human Gq-coupled M3 muscarinic receptor
(hM3Dq), have greatly facilitated our ability to directly
link changes in cellular activity to altered physiology
and behavior. Here, we extend the hM3Dq toolkit
with recombinase-responsive mouse lines that
permit hM3Dq expression in virtually any cell type.
These alleles encode a fusion protein designed to
increase effective expression levels by concentrating
hM3Dq to the cell body and dendrites. To illustrate
their broad utility, we targeted three different gene-
tically defined cell populations: noradrenergic neu-
rons of the compact, bilateral locus coeruleus and
two dispersed populations, Camk2a+ neurons and
GFAP+ glia. In all three populations, we observed
reproducible expression and confirmed that activa-
tion of hM3Dq is sufficient to dose-dependently
evoke phenotypic changes, without extreme pheno-
types associated with hM3Dq overexpression. These
alleles offer the ability to non-invasively control activ-
ity of diverse cell types to uncover their function and
dysfunction at any developmental stage.
INTRODUCTION
Since their initial description less than 10 years ago (Armbruster
et al., 2007), the engineered G protein-coupled receptors known
as designer receptors exclusively activated by designer drugs
(DREADDs) have proven invaluable for linking cellular activity
to changes in physiology and behavior. Among the most
frequently used DREADDs is hM3Dq, a mutated Gq-coupled
human M3 muscarinic receptor that is activated exclusively by
the designer drug clozapine N-oxide (CNO), but not its native
ligand acetylcholine. By coupling to endogenous signal trans-
duction pathways, hM3Dq has provided insight into the uniqueThis is an open access article undfunctions of cells as diverse as neurons, glia, pancreatic b cells,
and hepatocytes (as reviewed in Urban and Roth, 2015). In neu-
rons, activation of hM3Dq by CNO leads to calcium influx and
increased cell firing, thereby promoting neuronal excitability
(Alexander et al., 2009). Thus, hM3Dq has been of particular
value for identifying the functions encoded by specific neurons
in the freely behaving animal.
Previous methods for delivery of hM3Dq to cells in vivo have
included viral vectors, transgenes, and targeted knockin mouse
lines (Urban and Roth, 2015; Zhu and Roth, 2014). Each of these
strategies drives hM3Dq expression at levels sufficient for
behavioral or physiological analyses, but each has limitations.
The most commonly usedmethod for delivery of hM3Dq is injec-
tion of viral vectors. Although these constructs often generate
very high levels of hM3Dq expression, overexpressionmay result
in extreme phenotypes of questionable physiological relevance.
Furthermore, the requirement for direct injection limits the use of
viruses prenatally and in juvenile/adolescent animals.Multiple in-
jections are required to target dispersed or bilateral cell popula-
tions, increasing the possibility of experimentally significant
trauma and variable expression among experimental subjects.
Some of the experimental limitations of viral vectors can be
overcome by the use of transgenes. Given an appropriate pro-
moter, transgene expression can be achieved non-invasively in
anatomically dispersed populations at any stage of develop-
ment. However, each targeted cell population requires genera-
tion of a unique transgenic line, and multi-copy transgene
arrays can result in unpredictable expression levels. In contrast,
single-copy knockin alleles, particularly recombinase-respon-
sive constructs, offer consistent, reproducible expression and
the broadest range of possible cellular targets by partnership
with existing cell-type-specific recombinase driver lines. How-
ever, expression levels of single-copy alleles are likely to be
lower than those achieved with viruses or transgenes.
To overcome these experimental challenges, we generated
two recombinase-responsive knockin alleles that complement
existing hM3Dq constructs by permitting non-invasive targeting
of hM3Dq to the cell body (soma) and dendrites of genetically
defined cells. This somatodendritic localization is designed toCell Reports 15, 2563–2573, June 14, 2016 Array 2563
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concentrate hM3Dq, thus increasing its effective expression
level. Our Cre-responsive allele permits expression of hM3Dq
in genetically defined cell populations by taking advantage of
the many available cell-type-specific Cre driver alleles. Because
control by a single recombinase defines relatively broad classes
of cells, we also have generated a Flp/Cre-responsive allele that
restricts hM3Dq to the narrow intersection of two broader re-
combinase expression domains. hM3Dq is expressed only in
those cells that have expressed Flp and Cre drivers, each
controlled by the promoters of different genes, thus allowing
functional manipulation of cell populations that cannot be
defined by a single gene.
In this paper, we confirm that both alleles permit expression of
an hM3Dq-mCherry fusion protein detectable at single-cell res-
olution in live and fixed tissue from embryos or adult mice.
Furthermore, we demonstrate the broad utility of the alleles in
three different cell populations: noradrenergic neurons of the
small, bilateral locus coeruleus (LC) and two dispersed cell
populations, Camk2a+ neurons and GFAP+ glia. In a proof-of-
principle experiment using our Flp/Cre-responsive allele, we
demonstrate that CNO increases neuronal firing of hM3Dq-ex-
pressing LC neurons in vitro. We then demonstrate the in vivo
effectiveness of the Flp/Cre-responsive allele by inducing anxi-
ety-like behavior observed following activation of LC neurons
(McCall et al., 2015). Next we evaluate the in vivo utility of our
Cre-responsive allele by evoking physiological signatures
ascribed to activation of Camk2a+ neurons (Alexander et al.,
2009) and GFAP+ glia (Agulhon et al., 2013), specifically hippo-
campal gamma oscillations and profound depression of body
temperature, respectively. Collectively, these findings demon-
strate that our hM3Dq alleles permit activation of genetically
defined cell populations in a reproducible, dose-dependent
manner and are valuable additions to the DREADD toolkit.
RESULTS
Generation of Flp/Cre and Cre Recombinase-
Responsive Alleles for Somatodendritic Targeting
of hM3Dq
To ensure expression of our Flp/Cre-responsive (Rosa-CAG-
FRT-lox-hM3Dq [RC::FL-hM3Dq]) and Cre-responsive (Rosa-
CAG-lox-hM3Dq [RC::L-hM3Dq]) alleles in a wide range of cell
types and developmental stages, we used a synthetic CAG pro-
moter (Niwa et al., 1991) and targeted the Gt(ROSA)26Sor locus
(Friedrich and Soriano, 1991) in mouse embryonic stem cells
(Figure 1A). In RC::FL-hM3Dq, an FRT-flanked transcriptional
stop cassette (Sauer, 1993) following the CAG promoter pre-
vents transcription of all downstream sequence until it is excised
by Flp recombinase. The allele also encodes EGFP and an
hM3Dq-mCherry fusion protein with a C-terminal epitope
(2ACT88) that mediates localization of the hM3Dq receptor to
the cell body (soma) and dendrites (Xia et al., 2003). To prevent
expression in the absence of Cre recombination, the hM3Dq-
mCherry cDNA is inverted in a Cre-dependent FLEx switch con-
sisting of two pairs of antiparallel lox sites (Atasoy et al., 2008;
Schn€utgen et al., 2003). Cre activity results in inversion of
hM3Dq-mCherry to the proper orientation for transcription.
RC::FL-hM3Dq expresses EGFP following Flp-mediated recom-2564 Cell Reports 15, 2563–2573, June 14, 2016bination and hM3Dq-mCherry after recombination by both Flp
and Cre. RC::L-hM3Dq lacks the FRT-flanked stop cassette
but is otherwise identical to RC::FL-hM3Dq. Therefore,
RC::L-hM3Dq expresses EGFP in the absence of recombinase
activity and hM3Dq-mCherry after Cre-mediated recombination.
Because the recombination events are irreversible, cells express
hM3Dq-mCherry continuously, even if recombinase expression
is transient. Thus, RC::L-hM3Dq expresses hM3Dq-mCherry in
broad populations of cells defined by a single promoter that
drives Cre expression. RC::FL-hM3Dq allows restriction of
hM3Dq-mCherry to more specific subpopulations defined by
shared expression of Flp and Cre driven by different promoters.
To confirm that the CAG promoter is broadly active and that
hM3Dq-mCherry expression is efficiently controlled by recombi-
nase activity, we examined EGFP and mCherry fluorescence in
RC::FL-hM3Dq and RC::L-hM3Dq embryos and adults. In the
absence of recombinase activity, we observed neither EGFP
nor mCherry expression in RC::FL-hM3Dq embryos (Figure 1B)
and adult brain (Figure S1) due to the intact stop cassette and
FLEx switch. Following germline excision of the FRT-flanked
stop cassette (RC::L-hM3Dq), we observed ubiquitous ex-
pression of EGFP, but nomCherry. Subsequent germline recom-
bination of the FLEx switch in RC::L-hM3Dq mice resulted in
ubiquitous mCherry expression in both embryos and adult
brain (Figures 1B and S1). Thus, the CAG promoter is active
throughout development, and both the FRT-flanked stop
cassette andCre-dependent FLEx switch are capable of control-
ling expression of the proteins encoded by our two alleles.
To demonstrate the widest possible expression of hM3Dq-
mCherry, we crossed RC::FL-hM3Dq to the ubiquitously ex-
pressed ACTB-Flpe (Rodrı´guez et al., 2000) and ACTB-cre
(Lewandoski et al., 1997) recombinase drivers. We observed
hM3Dq-mCherry expression in a wide variety of cell types
throughout the brain (Figure 2). Next we used cell-type-specific
drivers to testwhetherourallelescandirect somatodendritic local-
ization of hM3Dq-mCherry in restricted cell populations. We used
RC::L-hM3Dq in combination withCamk2a-cre (Tsien et al., 1996)
orGFAP-creERT2 (Casper et al., 2007) transgenes for expression
of hM3Dq-mCherry in neurons or glia, respectively. As expected,
mCherry fluorescence was restricted to the soma and dendrites
of neurons in the well-documented expression domain of the
Camk2a-cre-transgene (Sonner et al., 2005), including cortical
and hippocampal neurons (Figures 3A, 3B, and S2). Using the
glial-specific GFAP-creERT2 transgene, we observed restricted
mCherry fluorescence in the soma and processes of glia defined
byGfapexpression (Figures3CandS3). Todemonstrate intersec-
tional Flp/Cre control ofRC::FL-hM3Dq, we targeted a population
of noradrenergic neurons defined by a shared history of both
En1cre and DbhFlpo expression (Robertson et al., 2013). This
combination of recombinase drivers restricts hM3Dq-mCherry
expression toasubpopulationofnoradrenergicneurons (hereafter
designated LC complex), which encompasses 99.8% of the
compact LC and a portion of the dorsal subcoeruleus and A7
noradrenergic nuclei (Robertson et al., 2013; Plummer et al.,
2015). As expected, mCherry fluorescence was restricted to the
soma and dendrites of the LC complex (Figures 3D and S4). All
remaining noradrenergic neurons, expressing only DbhFlpo, were
labeled with EGFP (Figure S4).
Figure 1. Recombinase-Responsive Alleles
for Somatodendritic Targeting of hM3Dq
(A) Schematic diagrams of RC::FL-hM3Dq (Jack-
son Lab JAX#026942) and RC::L-hM3Dq (Jackson
Lab JAX#026943) shown in relation to the
Gt(ROSA)26Sor locus. In both alleles, a CAG
promoter drives gene expression. RC::FL-hM3Dq
expresses EGFP after Flp-mediated excision of the
FRT-flanked His3-SV40 stop cassette (STOP).
hM3Dq-mCherry fusion protein is expressed after
excision of the stop cassette and recombination of
lox2272 and loxP sites constituting the Cre-
dependent FLEx switch. RC::L-hM3Dq expresses
EGFP ubiquitously and hM3Dq-mCherry after
Cre-mediated recombination of the FLEx switch.
2ACT88, C-terminal fragment of HTR2A; WPRE,
woodchuck hepatitis virus posttranscriptional
regulatory element; poly(A), bovine growth hor-
mone polyadenylation signal.
(B) Native EGFP and mCherry fluorescence in
E11.5 embryos. Top: absence of fluorescence in
RC::FL-hM3Dq heterozygote confirms that the
FRT-flanked stop cassette blocks expression in
the absence of Flp activity. Middle: ubiqui-
tous EGFP fluorescence, but no mCherry, in
RC::L-hM3Dq heterozygote confirms that the
FLEx switch blocks hM3Dq expression in the
absence of Cre activity. Bottom: ubiquitous
mCherry fluorescence observed after crossing
RC::L-hM3Dq with a ubiquitously expressed
ACTB-cre transgene (Lewandoski et al., 1997)
confirms recombination of the Cre-dependent
FLEx switch. Scale bar, 2 mm.Unexpectedly, we observed faint mCherry fluorescence in
cerebellar Purkinje cells that have expressed En1cre, but not
DbhFlpo (Figure S5A). The absence of ectopic EGFP expression
suggested that the ectopic mCherry results from mRNA
splicing that occurs after Cre-mediated recombination of the
FLEx switch, rather than failure of the FRT-flanked stop
cassette. To test this hypothesis, we performed RT-PCR
analysis of cerebellum RNA and identified mRNA from
RC::FL-hM3Dq in cells that had recombined the FLEx switch
(Figure S5B). Due to a cryptic splice acceptor within the
hM3Dq cDNA, this mRNA encoded mCherry, but not the full
hM3Dq-mCherry fusion. These experiments confirm that our
alleles faithfully express hM3Dq-mCherry in the defined recom-
binase expression domains, demonstrating they can deliver
hM3Dq to a variety of cell types limited only by the availability
of Flp and Cre driver lines.Cell RSelective hM3Dq-Mediated
Activation of Noradrenergic
Neurons In Vitro
To evaluate whether the level of hM3Dq
expressed from RC::FL-hM3Dq is suffi-
cient to alter cellular activity, we carried
out whole-cell patch-clamp recordings
of noradrenergic neurons in the LC com-
plex that express either hM3Dq-mCherry
(En1cre; DbhFlpo; RC::FL-hM3Dq tripleheterozygotes) or EGFP (DbhFlpo; RC::FL-hM3Dq controls)
(Figure 4A). Fluorescence in the LC complex was readily de-
tected in acute slice preparations (Figure 4B). To evaluate
whether CNO would depolarize hM3Dq-expressing neurons,
we recorded in the presence of the Na+ channel blocker TTX
(500 nM) or TTX plus the L-type Ca2+ channel blocker nimodipine
(1 mm) to eliminate network effects and oscillations. Average
resting membrane potential was 56.0 ± 11.0 mV, consistent
with prior observations of LC neurons (Williams et al., 1984;
de Oliveira et al., 2010). Bath application of 10 mMCNO depolar-
ized hM3Dq-mCherry+ LC complex neurons recorded in TTX
(4.04 ± 0.91 mV, n = 5 neurons) or TTX + nimodipine (1.60 ±
0.27 mV, n = 4 neurons). The depolarization measured under
the two recording conditions was not statistically different
(p = 0.20), and therefore data were combined, yielding
an average depolarization of 2.95 ± 0.48 mV (Figure 4C). Ineports 15, 2563–2573, June 14, 2016 2565
Figure 2. Widespread Expression of
hM3Dq-mCherry after Recombination of
RC::FL-hM3Dq by Ubiquitous Flp and Cre
Driver Alleles
(A) Sagittal section of ACTB-cre; ACTB-Flpe;
RC::FL-hM3Dq brain immunolabeled for mCherry
(red) and the neuronal marker NeuN (white). Boxes
show location of magnified images (below).
Following ubiquitous recombinase expression,
mCherry is observed throughout the brain. Fluo-
rescence is attenuated in regions with a high
proportion of axons (e.g., corpus callosum),
consistent with somatodendritic targeting of
hM3Dq-mCherry. Scale bars, 2,000 mm (full
sagittal section) and 244 mm (magnified images).
(B) Sections of ACTB-cre; ACTB-Flpe; RC::FL-
hM3Dq brain immunolabeled for mCherry (red) and
markers of neuronal and glial subtypes (white).
hM3Dq-mcherry is observed in midbrain dopami-
nergic neurons labeled for tyrosine hydroxylase
(TH), cortical interneurons labeled for parvalbumin,
and astrocytes labeled for glial fibrillary acidic
protein (GFAP). Scale bar, 20 mm.contrast, CNO had no effect on membrane potential of EGFP+
control neurons (Figures 4B and 4C). Depolarization by 50 mM
NMDA, however, confirmed that these cells were healthy and
responsive (Figure 4B). In the absence of CNO, hM3Dq-
mCherry+ and EGFP+ neurons exhibited similar baseline
membrane potential, capacitance, and membrane and input
resistance (Figure 4C; data not shown), suggesting that mere
expression of hM3Dq-mCherry does not impact membrane
properties.
To test whether expression of hM3Dq is sufficient to evoke
neuronal firing, we next performed cell-attached recordings in
the absence of TTX and nimodipine. Bath application of CNO
(10 mM) increased the firing rate of hM3Dq-mCherry+ LCneurons
by an average of 75.6% ± 30.0% above baseline activity (0.91 ±2566 Cell Reports 15, 2563–2573, June 14, 20160.08 Hz; n = 6 cells; p < 0.001; Figures 4D
and 4E). To confirm that the ectopically
labeled Purkinje cells do not express
functional hM3Dq-mCherry fusion pro-
tein, we also performed whole-cell re-
cordings of these cells. Consistent with
our identification of a nonfunctional
mRNA, membrane potential of mCherry+
Purkinje cells was not altered by 10 mM
CNO (Figure S5C). Taken together,
these results demonstrate that the level
of hM3Dq-mCherry expressed from RC::
FL-hM3Dq permits chemogenetic activa-
tion of an intersectional subpopulation
defined by expression of Cre and Flp.
In Vivo Activation of the LCComplex
Induces Anxiety-like Behavior and
Suppresses Locomotion
We assessed the in vivo utility of our dual
recombinase-responsive allele by testingwhether expression of hM3Dq can alter anxiety-like behavior.
Optogenetic stimulation of LC neurons at high, tonic frequency
(5 Hz) prior to testing evokes anxiety-like behavior and sup-
presses locomotion (McCall et al., 2015). To test whether
hM3Dq would evoke similar responses, we treated mice with
CNO (1 or 5 mg/kg, intraperitoneally [i.p.]) or vehicle before
testing in the following three assays: the elevated plus maze
(EPM), light-dark box (LDB), and open-field test (OFT). In all three
assays, CNO dose-dependently evoked anxiety-like responses
and concomitantly suppressed locomotion of mice expressing
hM3Dq-mCherry in the LC complex (Figure 5; Table S1). CNO
at 5 mg/kg significantly induced anxiety-like behavior by
reducing exploration within the aversive areas of the tests,
including open arms of the EPM (Figure 5A), light compartment
Figure 3. Somatodendritic Targeting of hM3Dq-mCherry in Neurons
and Glia
(A) Hippocampal CA3 neurons in a Camk2a-cre; RC::L-hM3Dq brain im-
munolabeled for mCherry (red) and nuclear NeuN (white) are shown.
(B) Cortical neurons from a Camk2a-cre; RC::L-hM3Dq brain immunolabeled
for mCherry (red) and NeuN (white) are shown.
(C) Cortical astrocyte from a GFAP-CreERT2; RC::L-hM3Dq brain immunola-
beled for mCherry (red) and GFAP (white) is shown.
(D) Noradrenergic neuron from an En1Cre; DbhFlpo; RC::FL-hM3Dq brain im-
munolabeled for mCherry (red) and tyrosine hydroxylase (white). Images are
taken from coronal sections. Scale bars, 40 (A and B) and 20 mm (C and D).of the LDB (Figure 5B), and center zone of the OFT (Figures 5C
and S6) compared to vehicle. Both doses of CNO also sup-
pressed locomotion, as shown by reduced closed-arm entries
in the EPM and distance ambulated in LDB and OFT compared
to vehicle (Figure 5). CNO had no effect on behavioral perfor-
mance of all littermate controls (Figure S7). In addition, mice
expressing hM3Dq and all littermate controls were indistinguish-
able when treated with vehicle (Figure S7). Collectively, these
data demonstrate that RC::FL-hM3Dq faithfully expresses
hM3Dq at levels that permit sensitive control of an intersection-
ally targeted neuronal subpopulation and recapitulates behav-
ioral phenotypes evoked by optogenetic stimulation.
Dose-Dependent Activation of hM3Dq Drives Gamma
Oscillations in Hippocampal Neurons In Vivo
Next we assessed the efficacy of our single recombinase-
responsive allele by testing whether hM3Dq can activate a
dispersed neuronal population. In the original description of a
tetracycline-controlled hM3Dq transgene, hippocampal gamma
power was progressively evoked in Camk2a+ neurons following
escalating doses of CNO (Alexander et al., 2009). To determine
whether our Cre-responsive allele would evoke similar neural
activity, we used the Camk2a-cre transgene (Tsien et al., 1996)
to drive hM3Dq-mCherry expression (Figure 6A). We recorded
local field potentials in CA3 of the hippocampus of mice express-ing hM3Dq-mCherry in Camk2a+ neurons (Camk2a-cre; RC::L-
hM3Dq) and littermate controls. Consistent with the original
study, we found that CNO dose-dependently increased
hippocampal gamma power (50–80 Hz) in mice expressing
hM3Dq-mCherry (Figures 6B and 6C). Doses of CNO as low as
1 mg/kg increased peak gamma power compared to vehicle.
The 10-mg/kg dose significantly increased gamma power
20 min following CNO injection, and gamma returned to baseline
levels an hour thereafter (Figure 6C). In all littermate controls,
CNO had no effect on peak gamma power (Figure 6C). These re-
sults confirm that RC::L-hM3Dq can be used to efficiently and
precisely control the activity of neuronal populations at levels
measurable by in vivo electrophysiology.
In Vivo Activation of hM3Dq Expressed in Glia Elicits
Hypothermia
We further assessed the broad utility of RC::L-hM3Dq by target-
ing a dispersed population of non-neuronal cells. Activation of
hM3Dq expressed in glia by a GFAP-hM3Dq transgene previ-
ously has been shown to induce hypothermia (Agulhon et al.,
2013). To determine whether RC::L-hM3Dq can recapitulate
this effect, we used the tamoxifen-inducible GFAP-creERT2
transgene (Casper et al., 2007) to drive hM3Dq-mCherry ex-
pression in glia (Figure 7A). Hypothermia was observed in mice
expressing hM3Dq-mCherry inGfap+ glia starting at 40min after
injection of CNO (5 mg/kg) and persisted until the test was
stopped at 90 min due to dangerously low body temperature
(Figure 7B). In contrast, CNO did not alter body temperature in
littermate controls (Figure 7C). Furthermore, we observed no
effect of vehicle on body temperature (Figures 7B and 7C).
Collectively, these data demonstrate that RC::L-hM3Dq permits
activation of dispersed non-neuronal populations at levels suffi-
cient to evoke lasting physiological changes.
DISCUSSION
The experiments described here demonstrate that our Flp/Cre-
and Cre-responsive hM3Dq alleles are valuable additions to
the DREADD toolkit. The combination of CAG promoter and
fusion protein for somatodendritic targeting of hM3Dq drives
robust expression that is readily detected in live and fixed tissue
across development. As demonstrated by our experiments, this
level of expression is sufficient to non-invasively and dose-
dependently manipulate cellular activity in diverse cell types,
producing behavioral and physiological changes without
undesired phenotypes associated with hM3Dq overexpression.
A primary strength of DREADD technology is the ability tomanip-
ulate cellular activity in freely moving animals, but this advantage
is compromised by strategies that require invasive delivery of the
DREADD. For instance, viral injection of deep brain structures
can result in significant damage to overlying parenchyma and
even death of experimental animals. In contrast, our recombi-
nase-responsive hM3Dq alleles offer a truly non-invasive means
to activate genetically defined cells.
These alleles offer several important advantages not shared
by published hM3Dq alleles. RC::FL-hM3Dq offers intersec-
tional genetic control of hM3Dq expression, thus providing
increased spatial resolution by precise targeting of hM3Dq toCell Reports 15, 2563–2573, June 14, 2016 2567
Figure 4. Intersectional Genetic Strategy for Selective, Non-invasive Expression of hM3Dq and Activation of the LC Complex
(A) Schematic diagram ofRC::FL-hM3Dq, sagittal diagram of noradrenergic nuclei in the hindbrain, and coronal sections through the LC complex immunolabeled
for tyrosine hydroxylase (white), EGFP (green), and mCherry (red). Top: in the absence of recombinase expression, noradrenergic neurons are not labeled
by EGFP or mCherry. Middle: recombination of RC::FL-hM3Dq by DbhFlpo results in EGFP expression in noradrenergic neurons. Bottom: recombination of
RC::FL-hM3Dq by En1cre and DbhFlpo results in hM3Dq-mCherry expression in noradrenergic neurons of the LC complex.
(B) Top: acute hindbrain slices show endogenous expression of EGFP (DbhFlpo; RC::FL-hM3Dq) and hM3Dq-mCherry (En1cre; DbhFlpo; RC::FL-hM3Dq) in LC
complex neurons patched using Alexa350-filled electrodes (blue). Scale bar, 20 mm. Bottom: representative traces from whole-cell recordings taken from LC
neurons with TTX (500 nM) and nimodipine (1 mM) present are shown. Bath application of CNO (10 mM) depolarizes hM3Dq-mCherry+ neurons from resting
membrane potential (dashed line). CNO has no effect on membrane potential of EGFP+ neurons, but NMDA (50 mM) does induce depolarization.
(legend continued on next page)
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Figure 5. CNO Is Sufficient to Drive Anxiety-like Behavior and
Suppress Locomotion inMice Expressing hM3Dq-mCherry in the LC
Complex
(A–C) Behavioral data from elevated plus maze (A, EPM), light-dark box
(B, LDB), and open-field test (C, OFT). Data are mean ± SEM for vehicle-
(n = 18–21), 1 mg/kg CNO- (n = 16–20), and 5 mg/kg CNO- (n = 13–15) treated
En1cre; DbhFlpo; RC::FL-hM3Dq mice (***p < 0.001, **p < 0.01, and *p < 0.05
versus vehicle, Bonferroni; ++p < 0.01 versus vehicle and 1 mg/kg CNO,
Bonferroni). Exact p values list trends for a statistical difference versus vehicle.cell populations defined by a shared history of Cre and Flp re-
combinase expression. Unlike existing Cre-responsive hM3Dq
knockin alleles (Teissier et al., 2015; Jackson Laboratory Stock
026220, unpublished reagent from U. Hochgeschwender and
B. Roth), RC::FL-hM3Dq and RC::L-hM3Dq utilize a FLEx switch
for efficient control of expression, an mCherry fusion for endog-(C) Left: average millivolt depolarization by CNO (10 mM) from baseline recorded
mice) and EGFP+ (DbhFlpo; RC::FL-hM3Dq, n = 9 cells from four mice) LC comp
(10 mM) on membrane potential in individual mCherry+ and EGFP+ LC neurons (
(D) Representative trace of cell-attached recordings from an hM3Dq-mCherry+ n
(left), during (middle), and after (right) superperfusion of CNO. Dashed line indica
(E) Left: bath application of CNO (10 mM) increases firing rate of hM3Dq-mCherry
population data show the effect of CNO (10 mM) on firing rate in individual hM3Denous fluorescent labeling, and a 2ACT88 epitope for somato-
dendritic targeting. These features ensure reliable expression
of hM3Dq at levels that effectively permit both in vivo visualiza-
tion and activation of genetically defined cells.
Our characterization of RC::FL-hM3Dq and RC::L-hM3Dq
demonstrated that somatodendritic expression of hM3Dq can
be obtained in virtually any cell population across tissues and
developmental stages. We observed the expected expression
of mCherry and EGFP, confirming that the FRT-flanked stop
cassette and Cre-dependent FLEx switch provide tight recombi-
nase-responsive control of hM3Dq expression. Unexpectedly,
we observed ectopic mCherry fluorescence in Cre+, Flp
cerebellar Purkinje cells of En1cre; DbhFlpo; RC::FL-hM3Dq
mice. However, our RT-PCR and in vitro electrophysiology
experiments unequivocally demonstrated that functional
hM3Dq-mCherry is limited to the intersectional population of
noradrenergic neurons that share a history of both Flp and Cre
expression. Restriction of ectopic mCherry to a single cell type
within the broad En1cre expression domain suggests that any
ectopic fluorescence in other intersectional crosses will be simi-
larly limited and will not interfere with experiments.
We validated the in vivo functional capabilities of RC::FL-
hM3Dq and RC::L-hM3Dq in three distinct cell types. Activation
of hM3Dq expressed bilaterally in the LC complex dose-depen-
dently evoked anxiety-like behavior and suppressed locomotion,
consistent with results following unilateral high tonic (5-Hz)
optogenetic stimulation of the LC (McCall et al., 2015). The
subtle changes in anxiety and locomotion we observed were
not obscured by the complete behavioral arrest that was
reported following prolonged, high-frequency optogenetic
stimulation (>5 Hz) (Carter et al., 2010). Using RC::L-hM3Dq,
we dose-dependently induced gamma oscillations in Camk2a-
cre+ hippocampal neurons, consistent with results using the
tetracycline-controlled TRE-hM3Dq transgene (Alexander
et al., 2009). Notably, the changes in neural activity we observed
were not accompanied by limbic seizures, an extreme pheno-
type observed using the TRE-hM3Dq transgene. Additionally,
activation of hM3Dq in GFAP+ glia dose-dependently evoked
long-lasting changes in body temperature, consistent with prior
results (Agulhon et al., 2013).
While all of these phenotypic changes emerged on the time-
scale of minutes following activation of hM3Dq, their onset
differed across experiments. Given that systemically adminis-
tered CNO is rapidly observed in the brain (Bender et al.,
1994), this varied onset of phenotype is likely dependent on
the targeted cell type, phenotypic endpoint, and CNO dose em-
ployed. Our findings further suggest that levels of hM3Dq
expression also influence the onset of phenotype. For example,
the hypothermia we observed was slower to emerge than previ-
ously described using aGFAP-hM3Dq transgene (Agulhon et al.,in hM3Dq-mCherry+ (En1cre; DbhFlpo; RC::FL-hM3Dq, n = 9 cells from seven
lex neurons (**p < 0.01, t test). Right: population data show the effect of CNO
***p < 0.001, Bonferroni).
euron. Insets of trace show individual firing events in epochs occurring before
tes the average holding current.
+ neurons (En1cre; DbhFlpo; RC::FL-hM3Dq, n = 6 cells from three mice). Right:
q-mCherry+ LC neurons (***p < 0.001, t test).
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Figure 6. Dose-Dependent Induction of HippocampalGammaOscillations byCNO inMice Expressing hM3Dq-mCherry inCamk2a+Neurons
(A) Schematic diagram shows Cre-mediated recombination of the FLEx switch permitting hM3Dq-mCherry expression. Coronal section through the hippo-
campus of a Camk2a-cre; RC::L-hM3Dq double heterozygote, immunolabeled for mCherry (red) and NeuN (white), is shown. Scale bar, 500 mm.
(B) Spectrograms show frequency composition of local field potentials (LFPs) recorded from Camk2a-cre; RC::L-hM3Dq mice before, during, and after
administration of vehicle or CNO at 1 or 10 mg/kg i.p.
(C) LFP data were divided into 5-min time bins and power spectral densities were computed. Pre-CNO power was the average gamma power (50–80 Hz) across
0–25 min. The 25- to 30-min bin was not included for analysis because mice were handled and injected. Gamma power post-CNO injection was normalized to
pre-CNOpower. Peak gamma power was averaged across 65- to 80-min bins (i.e., 35–50min post-CNO) and normalized to pre-CNO.Micewere administered all
doses listed. Top: time course of gamma power for vehicle- and CNO-treated Camk2a-cre; RC::L-hM3Dq double heterozygotes is shown. The yellow
window indicates the time period during which CNO increased gamma power (n = 4 mice). Bottom: peak gamma power following CNO injection forCamk2a-cre;
RC::L-hM3Dq and littermate control mice demonstrates dose dependence (***p < 0.001 and *p < 0.05 versus vehicle, Bonferroni; +p < 0.05 versus both CNO
1 mg/kg and vehicle, Bonferroni).2013). This result, together with the absence of extreme pheno-
types like seizures or behavioral arrest in the other crosses, is
likely due to lower levels of hM3Dq expression from our single-
copy knockin allele compared to transgenic or viral delivery.
Taken together, these findings indicate that our hM3Dq alleles
modulate cellular activity to produce physiologically relevant
changes in behavior without untoward effects that impede or
confound interpretation.
In summary, RC::FL-hM3Dq and RC::L-hM3Dq take full
advantage of the power of DREADD technology to non-inva-
sively manipulate cellular activity. Our characterization of these
alleles demonstrates their capacity to target genetically defined
cell populations, regardless of anatomical location or distribu-2570 Cell Reports 15, 2563–2573, June 14, 2016tion. In addition, the ability to express hM3Dq at any time point
offers the opportunity to uncover the functional consequences
of cellular activation throughout development. Together, these
capabilities render the hM3Dq alleles broadly useful for control-
ling the activity of diverse cell types to uncover their function and
dysfunction.EXPERIMENTAL PROCEDURES
Procedures related to the use of mice were conducted according to NIH
guidelines and the National Research Council Guide for the Care and Use
of Laboratory Animals (Publication 85-23, revised 2013). The Institutional
Animal Care and Use Committees (IACUCs) of the NIEHS and University of
Figure 7. Activation of hM3Dq-mCherry in Glia Is Sufficient to Elicit
Hypothermia
(A) Schematic diagram shows Cre-mediated recombination of the FLEx switch
permitting hM3Dq-mCherry expression in glia of mice treated with tamoxifen.
(B) Decreased body temperature in GFAP-creErt2; RC::L-hM3Dq double
heterozygotes following CNO. Data are mean ± SEM for mice given
vehicle (n = 5) or CNO 1 and 5 mg/kg (n = 6) (*p < 0.05 versus vehicle,
Bonferroni; +p < 0.05 versus vehicle and CNO 1 mg/kg, Bonferroni).
(C) CNO has no effect on the body temperature of littermate controls (+p < 0.05
versus vehicle and CNO 1 mg/kg, Bonferroni).North Carolina approved all experiments. Detailed methods are provided in
the Supplemental Experimental Procedures.
Generation of Mouse Lines
To generate our targeting vector for homologous recombination in embryonic
stem cells, we first modified a Cre-dependent FLEx switch (Atasoy et al., 2008;
Schn€utgen et al., 2003) by insertion of an EGFP cDNA and rabbit b-globin
polyadenylation cassette between the 50 lox2272 and loxP sites. We amplified
FRT-flanked and rox-flanked His3-SV40 transcriptional stop cassettes, using
as the PCR template a pBS302 plasmid (Sauer, 1993) modified to remove the
internal MfeI site. The stop cassettes and FLEx switch containing EGFP were
then cloned into the Gt(ROSA)26Sor targeting vector pRC-RFLTG (Plummer
et al., 2015) after digestion with MluI and FseI. The digested fragment of
pRC-RFLTG provided a CAG promoter (Niwa et al., 1991), woodchuck hepa-
titis virus posttranscriptional regulatory element (WPRE) (Zufferey et al., 1999),bGH poly(A) cassette, the 50 and 30 homology to the Gt(ROSA)26Sor locus,
and attB/attP-flanked Neo cassette. A cDNA encoding the hM3Dq-
mCherry-2ACT88 fusion protein, which contains the final 264 coding
nucleotides of the rat Htr2A gene (Xia et al., 2003), was generously provided
by Bryan Roth (University of North Carolina). This cDNA was cloned into the
center of the modified FLEx switch, in antisense orientation relative to the
CAG promoter and EGFP cDNA, to produce the final targeting vector
pRC-RFL-hM3Dq.
Linearized pRC-RFL-hM3Dq was electroporated into G4 embryonic stem
cells (George et al., 2007) obtained from the Lunenfeld-Tanenbaum Research
Institute, and long-range PCR and Southern blotting identified homologous
recombinants. A recombinant clone was transiently transfected with
pPGKPhiC31obpa (Raymond and Soriano, 2007) to remove the attb-attp-
flanked Neo cassette, and two subclones were injected into B6(Cg)-Tyrc-2J/J
blastocysts to produce chimeric mice. The RC::FL-hM3Dq strain was
established by breeding chimeras with B6;129-Tg(CAG-dre)1Afst mice
(Anastassiadis et al., 2009) to excise the rox-flanked stop cassette, and
the RC::L-hM3Dq strain was established by crossing RC::FL-hM3Dq
with B6.Cg-Tg(ACTFlpe)9205Dym/J mice (ACTB-Flpe) (Rodrı´guez et al.,
2000) to excise the FRT-flanked stop cassette. Both strains were maintained
by backcrossing to C57BL/6J mice. RC::FL-hM3Dq (JAX#026942) and
RC::L-hM3Dq (JAX#026943) mice will be available from the Jackson
Laboratory.
Experimental Crosses
To demonstrate ubiquitous expression of EGFP and hM3Dq-mCherry
encoded by our DREADD alleles, we crossed RC::FL-hM3Dq mice with
ACTB-Flpe followed by B6;FVB-Tg(ACTB-cre)2Mrt (ACTB-cre) (Lewandoski
et al., 1997). Embryos were collected at embryonic day (E) 11.5, and adult
organs were collected from 10-week-old mice. RC:L-hM3Dqmice were sepa-
rately crossed with B6(C3)-Tg(GFAP-cre/ERT2)13Kdmc (Casper et al., 2007)
and B6.Cg-Tg(Camk2a-cre)T29-1Stl (Tsien et al., 1996) mice. To generate
En1cre; DbhFlpo; RC::FL-hM3Dq mice, RC::FL-hM3Dq mice were first crossed
toB6;129-Dbhtm1(Flpo)Pjen (DbhFlpo) heterozygotes (Robertson et al., 2013), and
offspring were backcrossed to generate animals heterozygous forDbhFlpo and
homozygous for RC::FL-hM3Dq. The mice subsequently were crossed with
B6.Cg-En1tm2(cre)Wrst (En1cre) heterozygotes (Kimmel et al., 2000) to generate
En1cre; DbhFlpo; RC::FL-hM3Dq triple heterozygotes.
Tissue Collection and Immunohistochemistry
Embryos were fixed overnight by immersion in 4% paraformaldehyde (PFA) in
0.01 M PBS at 4C. Adult mice were anesthetized with sodium pentobarbital
(0.1 ml of 50 mg/ml i.p.) and perfused transcardially with PBS followed by
4% PFA in PBS. Brains were postfixed overnight by immersion in 4% PFA at
4C, and then rinsed in PBS before transfer to 30% sucrose in PBS for 48 hr
at 4C. Tissue for immunohistochemistry was embedded in Tissue Freezing
Medium (General Data) and sectioned at 40 mmon a Leica CM3050-S cryostat
(Leica Biosystems). Free-floating sections were collected for immunolabeling
using antibodies described in the Supplemental Experimental Procedures.
After staining, sections were mounted on microscope slides and coverslips
were attached with Vectashield or Vectashield plus DAPI (Vector Laboratories)
before imaging.
Digital Image Processing
Images of native fluorescence in whole embryos and adult brains were
collected on a Zeiss SteREO Lumar.V12 stereomicroscope (Carl Zeiss Micro-
scopy). Images of the LC complex from acute slices were acquired using a
Zeiss Axio Examiner microscope and camera (Axiocam 503) equipped with
Zen 2012 Blue Software (Carl Zeiss). The images of acute slices were pro-
cessed with ImageJ software (NIH) by merging color channels, adjusting
brightness and contrast, and applying a smoothing filter. Images of immuno-
fluorescent-labeled sections were collected on a Zeiss LSM 710, 780, or 880
inverted confocal microscope. Zen 2012 Black Software (Carl Zeiss) was
used to convert z stacks to maximum-intensity projections. Images were
modified only by brightness and contrast adjustments to optimize the full
dynamic range of the fluorescence signal. Anatomical location was confirmed
by reference to a mouse brain atlas (Paxinos and Franks, 2013).Cell Reports 15, 2563–2573, June 14, 2016 2571
Slice Electrophysiology
Following anesthesia of En1cre; DbhFlpo; RC::FL-hM3Dq and littermate mice,
coronal hindbrain slices (250 mm)were cut in ice-cold cutting solution and incu-
bated at 28–30C in oxygenated artificial cerebrospinal fluid (aCSF) for at least
30 min. All solutions are listed in the Supplemental Experimental Procedures.
Slices were transferred to a recording chamber and perfused with aCSF (32C)
at 2 ml/min. Patch electrodes (1–5 MU) were pulled from borosilicate glass. To
determine whether CNO (10 mM) would alter membrane potential, whole-cell
current-clamp recordings were made from EGFP+ and hM3Dq-mCherry+
LC neurons in the presence of TTX (500 nM) and nimodipine (1 mM). To confirm
the absence of functional hM3Dq, recordings were similarly made from
mCherry+ cerebellar Purkinje cells. Cell-attached voltage-clamp recordings
also were made from hM3Dq-mCherry+ LC neurons to quantify the increase
in firing events elicited by CNO (10 mM). Data were collected at 10 kHz using
an EPC 800 amplifier (HEKA) and DigiData 132x digitizer (Molecular Devices).
Analyses were performed in ClampFit 10.4 on traces that were filtered at 3 Hz
(voltage traces) or 1 Hz (current traces).
Anxiety-like Behavior
En1cre; DbhFlpo; RC::FL-hM3Dq and littermate mice were randomly assigned
to receive two i.p. injections of vehicle or CNO (1 or 5 mg/kg). Mice received
the first injection immediately before the OFT, and the second injection was
2–3 days later, 15 min before the LDB. Mice were tested in the EPM directly
after the LDB. Details of the tests are described below and in the Supplemental
Experimental Procedures.
OFT
Mice were placed in an open arena (27 3 27 3 20 cm, Med Associates)
that was not illuminated (0 lux). Exploration in the center (14.3 3 14.3 cm)
and remaining periphery of the arena was measured for 90 min.
LDB
Mice were allowed to freely explore an arena (27 3 27 3 20 cm, Med Associ-
ates) that was divided into two equal compartments. Exploration in the dark
(0 lux) and light (950 lux) compartments of the arena was measured for
10 min.
EPM
Mice were placed on a plus-shaped maze that was brightly illuminated
(300 lux) and elevated 20 in. Exploration in the open (11 3 2 in) and closed
(11 3 2 3 5 in) arms of the maze was measured for 5 min, as previously
described (Sciolino et al., 2015).
In Vivo Electrophysiology
A ten-channel array (44-mm polyimide-coated steel wires, Sandvic), soldered
to circuit board (San Francisco Circuits) and connector (Omnetics), was
implanted into the hippocampus of anesthetized Camk2a-cre; RC::L-hM3Dq
and littermate control mice using the following stereotaxic coordinates (mm):
2.06 anteroposterior, 2.1 mediolateral, and 2.1 dorsoventral from bregma
(Paxinos and Franks, 2013). Local field potentials were recorded using a
32-channel wireless headstage (Triangle BioSystems International) and Cere-
bus acquisition system (Blackrock Microsystems). During recordings, mice
were placed in a plexiglass chamber (20 3 20 in) and given an i.p. injection
of vehicle or the following escalating doses of CNO: 0.03, 0.1, 0.3, 0.5, 1, 5,
and 10 mg/kg, as previously described (Alexander et al., 2009). All mice
received each dose of CNO with 2–3 days between treatments. Analyses
were performed in MATLAB R2014a (MathWorks) using Chronux software
on traces that were band-pass filtered (0.3–500 Hz) and stored at 1 kHz.
Details are provided in the Supplemental Experimental Procedures.
Tamoxifen Dosing
Tamoxifen (T5648, Sigma-Aldrich) was dissolved in 10:1 corn oil:ethanol at a
concentration of 20 mg/ml (w/v). To induce Cre-mediated recombination,
GFAP-creERT2; RC::L-hM3Dq double heterozygous mice and littermate
controls received daily doses of tamoxifen (100 mg/kg i.p., 0.05 ml/10 g
body weight) for 5 days during postnatal weeks 6–12.
Body Temperature
Tamoxifen-treated GFAP-creErt2; RC::L-hM3Dq and littermate mice were
briefly restrained for baseline measurement of body temperature using a rectal2572 Cell Reports 15, 2563–2573, June 14, 2016probe. Following i.p. injection of vehicle or CNO (1 or 5 mg/kg), body temper-
ature wasmeasured in 10-min intervals for 90min. A heating pad was provided
to hypothermic mice after testing. All mice were tested twice with at least
5 days of recovery between the tests.
Data Analysis and Statistics
All data are reported as mean ± SEM. Datasets met normality (Shapiro-Wilk
test) and equal variance (Levine test) assumptions. Differences between
groups were determined using t tests or ANOVA. Bonferroni post hoc tests
were performed when necessary to correct for multiple comparisons. Signifi-
cance for all analyses was set to p < 0.05. Analyses were performed using
GraphPad Prism 6.0, MATLAB R2014a, and IBM SPSS 21.0. Details for the
analyses are described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.034.
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